13-CIS RETINOIC ACID AND INTERFERON ALPHA-2A IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA

Eleven patients, pre-treated with chemotherapy and immunotherapy, with renal cell carcinoma were given 13-cis-retinoic acid (CRA) in associa tion with interferon alfa-2a (IFN 2a). 13-cis-retinoic acid was admini stered at the dose of 1mg/Kg/die while interferon alfa-2a at the dose of 3x10 U.I./die s.c. All patients had been previously treated with ch emotherapy in association with immunotherapy. Therapy was not disconti nued until neoplastic progression occurred. Clinical results were as f ollows: partial responses (PR) were observed in two patients, disease stabilization (SD) in 5 and progression (PD), with 8-month median trea tment duration, in 4. Side effects were mild.